References
- Gassmann O, Schuhmacher A, von ZM, et al. Leading Pharmaceutical Innovation: How to Win the Life Science Race. 3rd ed. 2018, Springer International Publishing : Imprint: Springer, Cham, Germany. 2018.
- Lethaby A, Lopez-Olivo MA, Maxwell L, et al. Etanercept for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev. 2013;5:CD004525.
- Mazur M, Olek-Hrab K, Karczewski J, et al. Biosimilars in dermatology. Postepy Dermatol Alergol. 2015;32(5):384–387.
- Scott LJ. Etanercept: a review of its use in autoimmune inflammatory diseases. Drugs. 2014;74(12):1379–1410.
- Urquhart L. Top drugs and companies by sales in 2017. Nat Rev Drug Discov. 2018;17(4): 232–232.
- Beck A, Reichert JM. Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry. mAbs. 2013;5(5):621–623.
- Dutta B, Huys I, Vulto AG, et al. Identifying key benefits in European off-patent biologics and biosimilar markets: it is not only about price! BioDrugs Clin Immunother Biopharm Gene Ther. 2020;34(2):159–170.
- Rompas S, Goss T, Amanuel S, et al. Demonstrating value for biosimilars: a conceptual framework. Am Health Drug Benefits. 2015;8(3):129–139.
- Reinaud F, Ando G. PHP23 have infliximab discounted prices in Norway had an impact on prices around the world? Value Health. 2015;18(7):a518.
- DIQVIA Report 2018: The impact of biosimilar competition in Europe_docsroom - European commission [internet]. 2018 [cited 2021 May 22]; Available from: https://ec.europa.eu/docsroom/documents/31642
- Moorkens E, Simoens S, Troein P, et al. Different policy measures and practices between Swedish counties influence market dynamics: part 1—biosimilar and originator infliximab in the hospital setting. BioDrugs. 2019;33(3):285–297.
- Momenta Drops Biosimilar Adalimumab From Pipeline [Internet]. [ cited 2019 Aug 21] . Available from: https://www.centerforbiosimilars.com/news/momenta-drops-biosimilar-adalimumab-from-pipeline
- Rémuzat C, Dorey J, Cristeau O, et al. Key drivers for market penetration of biosimilars in Europe. J Mark Access Health Policy [Internet]. 2017 cited 2017 Nov 29;5(1). Available from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5328350/
- Fox A. Biosimilar medicines–new challenges for a new class of medicine. J Biopharm Stat. 2010;20(1):3–9.
- Biosimilars are coming. But, how similar are they really? [Internet]. Am. Counc. Sci. Health. 2015 [cited 2021 May 22]; Available from: https://www.acsh.org/news/2015/01/08/biosimilars-coming-similar-really
- Alten R, Cronstein BN. Clinical trial development for biosimilars. Semin Arthritis Rheum. 2015;44(6,Supplement):S2–8.
- Gomollón F. Biosimilars in inflammatory bowel disease: ready for prime time? Curr Opin Gastroenterol. 2015;31(4):290–295.
- Lopetuso LR, Gerardi V, Papa V, et al. Can We Predict the Efficacy of Anti-TNF-α Agents? Int J Mol Sci. 2017;18(9):9.
- Rungoe C, Langholz E, Andersson M, et al. Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979–2011. Gut. 2014;63(10):1607–1616.
- Danese S, Gomollon F. Governing Board and Operational Board of ECCO. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). J Crohns Colitis. 2013;7(7):586–589.
- Feagan BG, Choquette D, Ghosh S, et al. The challenge of indication extrapolation for infliximab biosimilars. Biol J Int Assoc Biol Stand. 2014;42(4):177–183.
- Ben-Horin S, Vande Casteele N, Schreiber S, et al. Biosimilars in Inflammatory Bowel Disease: facts and Fears of Extrapolation. Clin Gastroenterol Hepatol. 2016;14(12):1685–1696.
- Bokemeyer B, Dignaß A, Schreiber S. [Biosimilars in Inflammatory Bowel Disease (IBD): experiences and perceptions of German gastroenterologists]. Z Gastroenterol. 2017;55(4):369–374.
- Weise M, Kurki P, Wolff-Holz E, et al. Biosimilars: the science of extrapolation. Blood. 2014;124(22):3191–3196.
- Ebbers HC. Biosimilars: in support of extrapolation of indications. J Crohns Colitis. 2014;8(5):431–435.
- Danese S, Fiorino G, Raine T, et al. ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update. J Crohns Colitis. 2017;11(1):26–34.
- Lichtenstein G, Loftus E, Isaacs K, et al. Management of Crohn’s Disease in Adults. Am J Gastroenterol. 2018;113(4):481–517.
- Ye BD, Pesegova M, Alexeeva O, et al. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn’s disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet Lond Engl. 2019;393(10182):1699–1707.
- Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72(10):1613–1620.
- Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72(10):1605–1612.
- Industry Pulse: 10 charts on M&A, I/O and biosimilar threats [Internet]. BioPharma Dive. [ cited 2019 May 31]; Available from: https://www.biopharmadive.com/news/industry-pulse-10-charts-on-ma-io-and-biosimilar-threats/504115/
- Anonymous. AbbVie position on biosimilars [Internet]. [cited 2019 Sep]. Available from: https://www.abbvie.com/uploads/PDFs/Committed-to-Biologic-Innovation.pdf
- AbbVie’s plan to push Rinvoq to counter Humira biosimilar surge dampens [Internet]. [ cited 2021 May 22]; Available from: https://www.clinicaltrialsarena.com/comment/abbvies-plan-to-push-rinvoq-to-counter-humira-biosimilar-surge-dampens/
- House Committee Takes On Pricing, Patents for Top-Selling Drug Humira - WSJ [Internet]. [ cited 2021 May 24]; Available from: https://www.wsj.com/articles/house-committee-takes-on-pricing-patents-for-top-selling-drug-humira-11621345740?mod=searchresults_pos1&page=1
- Cohen H, Beydoun D, Chien D, et al. Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians. Adv Ther. 2017;33(12):2160–2172.
- Biosimilars approved in Europe/General/Biosimilars/Home - GaBI Online - Generics and Biosimilars Initiative [Internet]. [ cited 2019 May 31]; Available from: http://www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Europe
- Zhai MZ, Sarpatwari A, Kesselheim AS. Why Are Biosimilars Not Living up to Their Promise in the US? AMA J Ethics. 2019;21(8):E668–678.
- Disruption and maturity: the next phase of biologics [Internet]. [ cited 2019 May 31]; Available from: https://www.iqvia.com/-/media/iqvia/pdfs/nemea/uk/disruption_and_maturity_the_next_phase_of_biologics.pdf
- NHS England The NHS saves £324 million in a year by switching to better value medicines [Internet]. [ cited 2021 May 23]; Available from: https://www.england.nhs.uk/2018/07/nhs-saves-324-million-year-switching-to-better-value-medicines/
- NHS England NHS set to save record £300 million on the NHS’s highest drug spend [Internet]. [ cited 2021 May 23]; Available from: https://www.england.nhs.uk/2018/11/nhs-set-to-save-record-300-million-on-the-nhss-highest-drug-spend/
- European Medicines Agency. Guideline on Similar Biological Medicinal Products_CHMP/437/04 Rev 1. 2014. p. 1–7. Canary Wharf, London, United Kingdom.
- Jørgensen KK, Olsen IC, Goll GL, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet Lond Engl. 2017;389(10086):2304–2316.
- Danese S, Peyrin-Biroulet L. IBD: to switch or not to switch: that is the biosimilar question. Nat Rev Gastroenterol Hepatol. 2017;14(9):508–509.
- Goll GL, Jørgensen KK, Sexton J, et al. Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial. J Intern Med. 2019;285(6):653–669.
- Glintborg B, Loft AG, Omerovic E, et al. To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry. Ann Rheum Dis. 2019;78(2):192–200.
- Nikiphorou E, Kautiainen H, Hannonen P, et al. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther 2015;0:1–7.
- Pouillon L, Danese S, Hart A, et al. Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients. Aliment Pharmacol Ther. 2019;49(9):1181–1187.
- Bakalos G, Zintzaras E. Drug Discontinuation in Studies Including a Switch From an Originator to a Biosimilar Monoclonal Antibody: a Systematic Literature Review. Clin Ther. 2019;41(1):155–173.e13.
- Rezk MF, Pieper B. Treatment Outcomes with Biosimilars: be Aware of the Nocebo Effect. Rheumatol Ther. 2017;4(2):209–218.
- D’Amico F, Pouillon L, Argollo M, et al. Multidisciplinary management of the nocebo effect in biosimilar-treated IBD patients: results of a workshop from the NOCE-BIO consensus group. Dig Liver Dis. 2020;52(2):138–142.
- Cantini F, Benucci M. Switching from the bio-originators to biosimilar: is it premature to recommend this procedure? Ann Rheum Dis. 2019;78(4):e23–e23.
- Weise M, Bielsky M-C, De Smet K, et al. Biosimilars: what clinicians should know. Blood. 2012;120(26):5111–5117.
- Dörner T, Strand V, Cornes P, et al. The changing landscape of biosimilars in rheumatology. Ann Rheum Dis. 2016;75(6):974–982.
- Fiorino G, Manetti N, Armuzzi A, et al. The PROSIT-BIO Cohort: a Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar. Inflamm Bowel Dis. 2017;23(2):233–243.
- Azevedo V, Dörner T, Strohal R, et al. Biosimilars: considerations for clinical practice. Consid Med. 2017;1(1):13–18.
- Barbier L, Ebbers HC, Declerck P, et al. The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: a Systematic Review. Clin Pharmacol Ther. 2020;108(4):734–755.
- Calvo B, Zuñiga L. EU’s new pharmacovigilance legislation: considerations for biosimilars. Drug Saf. 2014;37(1):9–18.
- Pfizer. Post-Marketing observational cohort of patients with inflammatory bowel disease (IBD) treated with CT-P13 in usual practice (CONNECT-IBD) [Internet]. clinicaltrials.gov; 2020 [cited 2021 May 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT02539368
- One-year Persistence to Treatment of Participants Receiving Flixabi: a French Cohort Study - Full Text View - ClinicalTrials.gov [Internet]. [ cited 2019 Aug 23]; Available from: https://clinicaltrials.gov/ct2/show/NCT03662919
- National Observational Study On The Use Of InflectraTM An Infliximab Biosimilar In Real Life - Full Text View - ClinicalTrials.gov [Internet]. [ cited 2019 Aug 23]; Available from: https://clinicaltrials.gov/ct2/show/NCT02925338
- Kennedy NA, Heap GA, Green HD, et al. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn’s disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol. 2019;4(5):341–353.
- Kolbe AR, Kearsley A, Merchant L, et al. Physician Understanding and Willingness to Prescribe Biosimilars: findings from a US National Survey. BioDrugs Clin Immunother Biopharm Gene Ther. 2021;35(3):363–372.
- Vandenplas Y, Simoens S, Van Wilder P, et al. Informing Patients about Biosimilar Medicines: the Role of European Patient Associations. Pharmaceuticals Internet] 2021 [cited 2021 May 23];14(2). Available from. [];():117. : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913743/
- Fenwick S, Thakur K, Munro D. Nurse and Patient Perceptions and Preferences for Subcutaneous Autoinjectors for Inflammatory Joint or Bowel Disease: findings from a European Survey. Rheumatol Ther. 2019;6(2):195–206.
- Einarson TR, Bereza BG, Lee XY, et al. Dose escalation of biologics in Crohn’s disease: critical review of observational studies. Curr Med Res Opin. 2017;33(8):1433–1449.
- Putrik P, Ramiro S, Kvien TK, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis. 2014;73(1):198–206.
- Lakatos PL, Domenech E, Kellner H, et al. P484. Access to biologics and biosimilars across 11 European Union countries. J Crohns Colitis. 2016;10(suppl_1):S345–S345.
- Kobelt G, Kasteng F. Access to innovative treatments in rheumatoid arthritis in Europe. Rep Prep Eur Fed Pharm Ind Assoc EFPIA. 2009;2009:1–92.
- Schnellerer Therapie-Zugang für Rheuma-Patienten [Internet]. AG Biosimilars Co Generika EV. [ cited 2021 May 23]; Available from: https://probiosimilars.de/presse/zugang-zur-biologika-therapie-rheuma/
- Ebbers HC, Schellekens H. Are we ready to close the discussion on the interchangeability of biosimilars? Drug Discov Today. 2019;24(10):1963–1967.
- Kurki P, van AL, Wolff-Holz E, et al. Interchangeability of Biosimilars: a European Perspective. BioDrugs. 2017;31(2):83–91.
- Koyfman BH. Biosimilarity and Interchangeability in the Biologics Price Competition and Innovation Act of 2009 and FDA’s 2012 Draft Guidance for Industry. Biotechnol Law Rep. 2013;32(4):238–251.
- Wang J, Chow S-C. On the Regulatory Approval Pathway of Biosimilar Products. Pharmaceuticals. 2012;5(4):353–368.
- Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Considerations in Demonstrating Interchangeability With a Reference Product Guidance for Industry [Internet]. 2019 [cited 2019 Aug 26]; Available from: https://www.fda.gov/media/124907/download
- Gerdes S, Thaçi D, Griffiths CEM, et al. Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study. J Eur Acad Dermatol Venereol JEADV. 2018;32(3):420–427.
- McKinley L, Kelton JM, Popovian R. Sowing confusion in the field: the interchangeable use of biosimilar terminology. Curr Med Res Opin. 2019;35(4):619–621.
- Nabi H, Georgiadis S, Loft AG, et al. Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial. Ann Rheum Dis. 2021;annrheumdis-2021-219951. DOI:https://doi.org/10.1136/annrheumdis-2021-219951
- Beyer B, Walch N, Jungbauer A, et al. How Similar Is Biosimilar? A Comparison of Infliximab Therapeutics in Regard to Charge Variant Profile and Antigen Binding Affinity. Biotechnol J. 2019;14(4):1800340.
- European Medicines Agency. EMA/CHMP/793732/201_Summary of opinion (initial authorisation) Flixabi, INN - Infliximab [Internet]. 2016 [cited 2016 Jul 29]; Available from: https://www.ema.europa.eu/en/documents/assessment-report/flixabi-epar-public-assessment-report_en.pdf
- Ruiz-Argüello MB, Maguregui A, del AAR, et al. Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars. Ann Rheum Dis. 2016;;75:1693-1696.
- Mehr S. Subcutaneous Infliximab Biosimilar Being Tested by Celltrion–BR&R [Internet]. 2018 [cited 2019 Jun 6]; Available from: https://biosimilarsrr.com/2018/06/19/will-celltrion-subcutaneous-infliximab-pave-new-biosimilar-road/
- Kim H, Alten R, Cummings F, et al. Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters. mAbs. 2021;13(1):1868078.
- Sands BE, Peyrin-Biroulet L, Loftus EV, et al. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. N Engl J Med. 2019;381(13):1215–1226.
- Hofmann H-P, Kronthaler U, Fritsch C, et al. Characterization and non-clinical assessment of the proposed etanercept biosimilar GP2015 with originator etanercept (Enbrel®). Expert Opin Biol Ther. 2016;16(10):1185–1195.
- Gray CS. Seeking Meaningful Innovation: lessons Learned Developing, Evaluating, and Implementing the Electronic Patient-Reported Outcome Tool. J Med Internet Res. 2020;22(7):e17987.
- European Medicines Agency. Biosimilars in the EU - Information guide for healthcare professionals. 40. Canary Wharf, London, United Kingdom.
- Perpoil A, Grimandi G, Birklé S, et al. Public Health Impact of Using Biosimilars, Is Automated Follow up Relevant? Int J Environ Res Public Health. 2020;18(1):1.
- Courage N, Parsons A. The Comparability Conundrum: biosimilars in the United States, Europe and Canada. Food Drug Law J. 2011;66(2):203–224.
- Süle A, Jørgensen F, Horák P, et al. Biosimilar medicines. Eur J Hosp Pharm Sci Pract. 2019;26(2):117–118.
- Verma S, Jain P, Chauhan P. Biobetters: the Better Biologics and Their Regulatory Overview. Int J Drug Regul Aff. 2018;4(1):13–20.
- Frapaise F-X. The End of Phase 3 Clinical Trials in Biosimilars Development? BioDrugs Clin Immunother Biopharm Gene Ther. 2018;32(4):319–324.
- Schiestl M, Ranganna G, Watson K, et al. The Path Towards a Tailored Clinical Biosimilar Development. BioDrugs Clin Immunother Biopharm Gene Ther. 2020;34(3):297–306.
- AL-Sabbagh A, Olech E, McClellan JE, et al. Development of biosimilars. Semin Arthritis Rheum. 2016;45(5,Supplement):S11–8.
- Payers’ price & market access policies supporting a sustainable biosimilar medicines market [Internet]. Simon-Kucher-2016-Policy-Requir.—Sustain.-Biosimilar-Mark.-FINAL-Report for-Publ. 2016 [cited 2021 May 24]; Available from: https://www.medicinesforeurope.com/wp-content/uploads/2016/09/Simon-Kucher-2016-Policy-requirements-for-a-sustainable-biosimilar-market-FINAL-report_for-publication2.pdf
- Mulcahy AW, Hlavka JP, Case SR. Biosimilar Cost Savings in the United States: initial Experience and Future Potential. Rand Health Q. 2018;7(4):3.
- Ivanova H, Macaulay R. PMU64 Unlocking Access for Transformational CAR-T Cell and Gene Therapies. Are Biosimilars The Key? Value Health. 2019;22:S719.